Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 10/20 | 0.66 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247913 | 0.89 | NPBWR1 (0.57) | GHSR | |
| SCHEMBL30974046 | 0.89 | GHSR (0.63) | GHSR | |
| SCHEMBL30617730 | 0.88 | GHSR (0.62) | GHSRUTS2R | |
| SCHEMBL26444818 | 0.88 | GHSR (0.82) | GHSR | |
| SCHEMBL31238554 | 0.86 | GHSR (0.64) | GHSR | |
| SCHEMBL31018677 | 0.86 | GHSR (0.57) | GHSRUTS2R | |
| SCHEMBL29695659 | 0.84 | GHSR (0.58) | GHSR | |
| SCHEMBL31202576 | 0.84 | GHSR (0.66) | GHSRUTS2R | |
| SCHEMBL30093010 | 0.83 | GHSR (0.63) | GHSR | |
| SCHEMBL24739439 | 0.83 | GHSR (0.57) | GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400638-A1 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | MAGNI GUIDO (CH) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400638-A1 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | AVPR2, RXFP1, RXFP2 | GHSR 83/4885UTS2R 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.